"HERDOO2" clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any d-Dimer?

Abstract:

BACKGROUND:The "HERDOO2 rule" is a prospectively validated clinical decision rule used to identify low-risk women who can safely discontinue anticoagulants after completing 5-12 months of anticoagulant treatment for unprovoked venous thromboembolism. The VIDAS®d-Dimer (DD) assay, a component of the rule, was used in the derivation and validation of the rule at half the usual diagnostic cut-point for exclusion of venous thrombosis. It is unknown if other commercial DD assays used at a corresponding cut-point will categorize patients at high concordance with the VIDAS® DD. OBJECTIVE:To determine if other available automated quantitative DD assays have high enough concordance with the VIDAS® DD assay to allow their use within the "HERDOO2" clinical decision rule. METHODS:Frozen plasma samples from a sub-set (n = 248) of female participants in the "HERDOO2" validation study were tested using five DD assays: VIDAS®, Innovance®, HemosIL®, Tina-quant® and Liatest®, with duplicate testing for 50 samples. First, using the mean DD for 50 samples with duplicate results, we determined the optimal cut-point values for each test that corresponded with a VIDAS® DD result of 250 μg/L using linear regression analysis. Next, kappa analysis was conducted on the DD results of the remaining 198 samples to determine concordance between each tested DD at the respective optimal cut-point and the VIDAS® DD at 250 μg/L. In a separate analysis we determined the concordance at half the usual venous thrombosis exclusion cut-point. RESULTS:Regression analysis of the DD results in 50 samples identified the optimal cut-point for each DD assay to match a VIDAS® DD cut-point of 250 μg/L: Innovance® 177 μg/L, Liatest® 233 μg/L, Tina-quant® 48 μg/L and HemosIL® 56 μg/L. Next, in 198 different samples, the concordance of VIDAS® DD (≥250 μg/L or <250 μg/L) was explored at the optimal cut-point of the other DD assays. The concordance was poor for all DD assays: Innovance® (kappa 0.38 (95% CI, 0.26-0.51)), Liatest® (kappa 0.38 (95% CI, 0.25-0.50)), HemosIL® (kappa 0.36 (95% CI, 0.23-0.49)) and Tina-quant® (kappa 0.30 (95% CI, 0.16-0.43)). Similar poor concordance was identified using half of the diagnostic DD cut-point for each tested assay: Innovance® (kappa 0.44 (95% CI, 0.32-0.56)), Liatest® (kappa 0.38 (95% CI, 0.25-0.51)), HemosIL® (kappa 0.04 (95% CI, -0.01-0.08)) and Tina-quant® (kappa 0.04 (95% CI, -0.004-0.07)). CONCLUSION:The "HERDOO2 rule" is the only prospectively validated clinical decision rule that can be used to identify low-risk women with unprovoked venous thrombosis who can safely discontinue anticoagulants. An important implementation issue is whether any commercial DD assay can be used in the HERDOO2 rule, and at what cut-point. Our analysis shows that the HemosIL®, Innovance®, Liatest® and Tina-quant® DD assays should not be used in the "HERDOO2" rule due to poor concordance with the VIDAS® DD assay and unacceptable misclassification of women at high and low risk of recurrent venous thrombosis.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Rodger MA,Le Gal G,Langlois NJ,Gin B,Mallick R,Giulivi A,Freedman M,Kovacs MJ,REVERSE II investigators.

doi

10.1016/j.thromres.2018.07.020

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

82-86

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(18)30435-3

journal_volume

169

pub_type

杂志文章
  • Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.

    abstract::Selected coagulation and fibrinolytic parameters were assessed in 40 insulin dependent diabetes mellitus patients with varying degrees of metabolic control; 30 healthy subjects matched for age and sex formed the control group. Activated Partial Thromboplastin Time, Prothrombin Time, Fibrinogen, Factor VII, Antithrombi...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(92)90068-l

    authors: Carmassi F,Morale M,Puccetti R,De Negri F,Monzani F,Navalesi R,Mariani G

    更新日期:1992-09-15 00:00:00

  • Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.

    abstract:INTRODUCTION:Recombinant members of the vitamin K-dependent protein family (factors IX and VII and protein C) have become important pharmaceuticals in treatment of bleeding disorders and sepsis. However, because the in vivo gamma-carboxylation system in stable cell lines used for transfection has a limited capacity of ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2007.11.002

    authors: Wajih N,Owen J,Wallin R

    更新日期:2008-01-01 00:00:00

  • Recombinant human protein C: comparative functional studies with human plasma protein C.

    abstract::Protein C (PC) is the central protein in a major antithrombotic regulatory mechanism. Hereditary deficiencies of PC are associated with thrombosis. Therapeutic PC replacement may be an important treatment if pure functional human protein C is available in sufficient quantity. Human PC has been produced on a commercial...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(90)90258-e

    authors: Madden RM,Oppenheimer C,Wydro R,Marlar RA

    更新日期:1990-02-01 00:00:00

  • Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.

    abstract::Current guidelines recommend performing laboratory tests aimed at monitoring unfractionated heparin (UFH) treatments within a delay not exceeding 1 to 2 h(s) after sampling when blood is collected into citrated tubes. As such a short delay could be an issue, we evaluated the potential impact of longer delays. For that...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2019.10.019

    authors: Toulon P,Appert-Flory A,Fischer F,Buvat S,Jambou D,Mahagne MH

    更新日期:2020-02-01 00:00:00

  • Effects of fibrinogen and platelet supplementation on clot formation and platelet aggregation in blood samples from cardiac surgery patients.

    abstract:INTRODUCTION:Bleeding after cardiac surgery may be caused by surgical factors, impaired haemostasis, or a combination of both. Transfusion of blood products is used to improve haemostasis, but little is known about what combination is optimal. We hypothesized that addition of both fibrinogen and platelets to blood samp...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2014.05.023

    authors: Shams Hakimi C,Fagerberg Blixter I,Hansson EC,Hesse C,Wallén H,Jeppsson A

    更新日期:2014-10-01 00:00:00

  • Clinical study of optical coherence tomography in the diagnosis of peripheral pulmonary artery thrombus.

    abstract:BACKGROUND:Peripheral pulmonary artery thrombus (PPT) is common in the clinic. However, due to the lack of an ideal diagnostic tool, PPT cannot be quickly diagnosed and effectively treated at present. Optical coherence tomography (OCT) is a new intravascular imaging technique that is characterized by high image resolut...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2017.10.021

    authors: Hong C,Luo FQ,Liu CL,Zhong NS,Li JY,Wang W

    更新日期:2018-01-01 00:00:00

  • "A" subunit of factor XIII is present on bovine platelet membrane and mediates collagen-induced platelet activation.

    abstract::The Fab fragment of a polyclonal antibody against platelet factor XIII inhibited the collagen-induced platelet aggregation in a dose-dependent manner. This inhibitory effect was specific for collagen, and it had no effect on arachidonic acid-, ADP-, and serotonin-induced aggregations. This finding strengthens our noti...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(88)90226-5

    authors: Kasahara K,Takagi J,Sekiya F,Inada Y,Saito Y

    更新日期:1988-04-15 00:00:00

  • Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.

    abstract::Recombinant factor IX (rFIX) is increasingly used to treat patients with hemophilia B. CHO (Chinese Hamster Ovary) cells are commonly used for the production of rFIX but they have a limited capacity for introducing post-translational modifications (PTM) leading to incomplete γ-carboxylation, low phosphorylation and su...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2012.08.313

    authors: Enjolras N,Dargaud Y,Pérot E,Guillaume F,Becchi M,Négrier C

    更新日期:2012-11-01 00:00:00

  • Collagen derived octapeptide inhibits platelet procoagulant activity induced by the combined action of collagen and thrombin.

    abstract::Platelet prothrombin converting activity was measured in a system using washed human platelets and purified coagulation factors Xa, Va and prothrombin. Exposure of platelet prothrombin converting activity evoked by collagen or the combined action of collagen and thrombin was effectively inhibited when a collagen deriv...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(85)90065-9

    authors: Bevers EM,Karniguian A,Legrand YJ,Zwaal RF

    更新日期:1985-02-01 00:00:00

  • Immunohistochemical localization of plasminogen activators in human saphenous veins.

    abstract::Human saphenous veins were analyzed for presence of plasminogen activators (t-PA) in the endothelium of the vessel walls by immunohistochemical techniques. We used a polyclonal rabbit antihuman t-PA antibody, a monoclonal mouse-antihuman t-PA and a goat antibody to low molecular weight urokinase. To demonstrate presen...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(86)90240-9

    authors: Risberg B,Eriksson E,Björk S,Hansson GK

    更新日期:1986-02-01 00:00:00

  • Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA.

    abstract::Stent implantation after balloon dilation of coronary arteries has improved clinical prognosis in patients undergoing transluminal coronary angioplasty (PTCA), but late restenosis remains a relevant problem. A previous study has indicated that PAI-1 activity changes immediately after PTCA without stent implantation ar...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0049-3848(01)00360-7

    authors: Prisco D,Fedi S,Antonucci E,Capanni M,Chiarugi L,Chioccioli M,Falai M,Giglioli C,Abbate R,Gensini GF

    更新日期:2001-11-01 00:00:00

  • Hemorrhagic and thrombotic complications in bone marrow transplant recipients.

    abstract::Hemostatic challenges occur throughout the period of stem cell transplantation (SCT). Endothelial cells injury due to chemotherapy, growth factors, intravenous catheter, and graft-versus-host disease and profound thrombocytopenia are the major components involved in the hemostatic complications. Diffuse alveolar hemor...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/S0049-3848(07)70136-6

    authors: Nadir Y,Brenner B

    更新日期:2007-01-01 00:00:00

  • Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteins.

    abstract::Heparin cofactor II (HCII) is a specific thrombin inhibitor; its inhibitory activity is stimulated by heparin (Hep) and dermatan sulfate (DS). Vitronectin (VN), a heparin binding adhesive glycoprotein present in plasma and extracellular matrix, has been shown to decrease the stimulatory effect of Hep but not of DS on ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(92)90310-7

    authors: Petzelbauer E,Seiffert D,Beckmann R,Pusch B,Geiger M,Binder BR

    更新日期:1992-06-01 00:00:00

  • The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.

    abstract::Epidemiological studies have shown that oral contraceptives increase the risk of thromboembolic disease in susceptible women however the mechanisms involved are unclear. We investigated whole blood platelet aggregation in 44 women randomly allocated to 6 cycles of treatment with either gestodene (75ug) or desogestrel ...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0049-3848(96)00013-8

    authors: Norris LA,Devitt M,Bonnar J

    更新日期:1996-02-15 00:00:00

  • Studies on the anticoagulant action of Aspilia africana.

    abstract::An anticoagulant activity was identified and isolated from the leaves of a West African plant, Aspilia africana by gel filtration on Sephadex G-100. The anticoagulant factor had an apparent molecular weight of approximately 60,000 d. Upon incubation with plasma, it prolonged the partial thromboplastin time, prothrombi...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(87)90455-5

    authors: Hanna MM,Niemetz J

    更新日期:1987-08-15 00:00:00

  • New families with von Willebrand disease type 2M (Vicenza).

    abstract::The variant von Willebrand disease (vWd) variant type 2M (Vicenza) was identified in 13 patients of 7 unrelated families. 11 patients were from different parts of germany and 2 patients from Turkey. Hitherto this variant of vWd has been described only in two families originating from the province of Vicenza in Norther...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(97)00104-7

    authors: Zieger B,Budde U,Jessat U,Zimmermann R,Simon M,Kätzel R,Sutor AH

    更新日期:1997-07-01 00:00:00

  • Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.

    abstract:BACKGROUND:Arterial calcification is associated with increased risk of cardiovascular events. Osteoprotegerin (OPG) is a cytokine involved in the bone metabolism and vascular calcification. Recent data support a relationship between high serum levels of OPG and increased risk for cardiovascular disease in human. The ai...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2006.12.004

    authors: Guldiken B,Guldiken S,Turgut B,Turgut N,Demir M,Celik Y,Arikan E,Tugrul A

    更新日期:2007-01-01 00:00:00

  • The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.

    abstract::A new method, based on the observation that leukocytes contain PGI2-synthetase activity, was used to measure the effect of pharmacological levels of sulphinpyrazone on the TXA2 and PGI2 production in whole blood. Four human volunteers took 400 mg sulphinpyrazone twice daily for 5 1/2 days. Blood was drawn before the s...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(82)90033-0

    authors: Badenhorst PN,Deckmyn H,Vermylen J

    更新日期:1982-10-01 00:00:00

  • First visualization of circulating neutrophil extracellular traps using cell fluorescence during human septic shock-induced disseminated intravascular coagulation.

    abstract::Disseminated intravascular coagulation (DIC) is a severe complication of septic shock. Polymorphonuclear neutrophils (PMNs) may play a key role in septic shock-induced DIC via the release of neutrophils extracellular traps (NETs). NETs capture invading pathogens, but also act as a pro-coagulant surface at the interfac...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2019.09.036

    authors: Stiel L,Mayeur-Rousse C,Helms J,Meziani F,Mauvieux L

    更新日期:2019-11-01 00:00:00

  • Should we abandon the APTT for monitoring unfractionated heparin?

    abstract:INTRODUCTION:The activated partial thromboplastin time (APTT) is commonly used to monitor unfractionated heparin (UFH) but may not accurately measure the amount of heparin present. The anti-Xa assay is less susceptible to confounding factors and may be a better assay for this purpose. MATERIALS AND METHODS:The validit...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2017.07.006

    authors: Arachchillage DRJ,Kamani F,Deplano S,Banya W,Laffan M

    更新日期:2017-09-01 00:00:00

  • Heparanase procoagulant effects and inhibition by heparins.

    abstract::Heparanase is an endo-beta-D-glucuronidase capable of cleaving heparan sulfate (HS) side chains of heparan sulfate proteoglycans (HSPG) on cell surfaces and the extracellular matrix, activity that is strongly implicated in tumor metastasis and angiogenesis. Evidence was provided that heparanase over-expression in canc...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/S0049-3848(10)70018-9

    authors: Nadir Y,Brenner B

    更新日期:2010-04-01 00:00:00

  • Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation.

    abstract::Beta-thromboglobulin (beta-TG) is a platelet-specific protein present in the alpha-granules and secreted into the surrounding medium on cell activation. The sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of platelet releasate after inhibition of metalloproteinases with ethyleneglycol-bis-(beta-a...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(02)00135-4

    authors: Resmi KR,Krishnan LK

    更新日期:2002-05-15 00:00:00

  • Inhibition by luciferin-luciferase reagents of aggregatory responses to excitatory agonists in washed platelet suspensions.

    abstract::Addition of two commercial luciferin-luciferase reagents caused marked inhibition of the aggregatory response of washed human platelets to thrombin, ADP, vasopressin and platelet-activating factor (PAF). Analysis of the effects of the individual components of one of these reagents revealed that Mg2+, and to a lesser e...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(85)90053-2

    authors: Thompson NT,Scrutton MC

    更新日期:1985-04-15 00:00:00

  • Symptomatic and asymptomatic deep vein thrombosis after total hip replacement. Differences in phlebographic pattern, described by a scoring of the thrombotic burden.

    abstract::The aim was to describe the phlebographic pattern of asymptomatic and symptomatic deep vein thrombosis (DVT) after total hip replacement by the use of a scoring system in 102 consecutive patients (54 asymptomatic, 48 symptomatic). The DVTs were scored from 1 to 3, and registered in a scoring system dividing the deep v...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(00)00274-7

    authors: Björgell O,Nilsson PE,Benoni G,Bergqvist D

    更新日期:2000-09-01 00:00:00

  • Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.

    abstract:INTRODUCTION:Randomized clinical trials have demonstrated non-inferiority of rivaroxaban compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism (VTE). Our objective was to analyze in real life, tolerance, recurrence, bleeding and adverse events of rivaroxaban in patients with acute sympto...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2014.06.032

    authors: Jara-Palomares L,Sanchez-Oro-Gomez R,Elias-Hernandez T,Morillo-Guerrero R,Ferrer-Galvan M,Asensio-Cruz MI,Barrot-Cortes E,Otero-Candelera R

    更新日期:2014-09-01 00:00:00

  • Genetic score based on high-risk genetic polymorphisms and early onset of ischemic heart disease in an Italian cohort of ischemic patients.

    abstract::Several single-nucleotide polymorphisms (SNPs) have been recognized as associated with ischemic heart disease (IHD) although the optimal set of risk genotypes has not be identified. This study aimed to examine whether identified high-risk SNPs are associated with early onset of IHD. In the GENOCOR study, 44 high-risk ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2014.03.006

    authors: Vecoli C,Adlerstein D,Shehi E,Bigazzi F,Sampietro T,Foffa I,Carpeggiani C,L'abbate A,Andreassi MG

    更新日期:2014-05-01 00:00:00

  • Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study.

    abstract:BACKGROUND:Statins have been shown to have a protective effect for venous thromboembolism (VTE) in the general population. This study sought to assess the association between statins and the risk for cancer-associated deep vein thrombosis (DVT) and pulmonary embolism (PE). METHODS:Patients with newly diagnosed cancer ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2017.08.001

    authors: El-Refai SM,Black EP,Adams VR,Talbert JC,Brown JD

    更新日期:2017-10-01 00:00:00

  • Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy.

    abstract::The treatment of prostatic cancer with oestrogen has been reported to be associated with cardiovascular side effects. Twenty patients with recently diagnosed prostatic cancer were randomly allocated to oestrogen therapy or orchidectomy. As compared to healthy age matched controls the patients with prostatic cancer had...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0049-3848(86)90024-1

    authors: Henriksson P,Blombäck M,Bratt G,Edhag O,Eriksson A

    更新日期:1986-12-15 00:00:00

  • Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.

    abstract::Four calcium channel blockers (nimodipine, nifedipine, verapamil and diltiazem) of three chemical classes were tested in vitro for inhibition of platelet aggregation using heparinized human platelet rich plasma. Both ADP- and thrombin-induced aggregation were inhibited as was the biosynthesis of thromboxane A2 in resp...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(84)90241-x

    authors: Onoda JM,Sloane BF,Honn KV

    更新日期:1984-06-01 00:00:00

  • Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.

    abstract:INTRODUCTION:In the treatment of bleeds in haemophilia patients with inhibitors, a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been per...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.11.002

    authors: Salaj P,Kubes R,Cetkovsky P,Capova I,Penka M,Ovesná P,Mesterton J,Lindgren P

    更新日期:2014-02-01 00:00:00